← SynDRA
CERITINIB
SynDRA canonical compound SYN0037441 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · Rx |
|---|
| Primary target(s) | ALK |
|---|
| Mechanism of action | ALK inhibitor |
|---|
| Indication | non-small cell lung cancer (NSCLC) |
|---|
| Disease area | oncology |
|---|
All known targets
- ALK
- TSSK1B
- INSR
- IGF1R
- FLT3
- ABCB1
- PLK4
- MAPK7
- MET
- MKNK2
- NPM1
- NTRK1
Mechanisms of action (all sources)
- ALK INHIBITOR
- ALK tyrosine kinase receptor inhibitor
- EML4 INHIBITOR
- NPM1 INHIBITOR
- FLT3 INHIBITOR
- IGF1R INHIBITOR
- INSR INHIBITOR
- TSSK1B INHIBITOR
- ALK MODULATOR
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- CYP3A4
- ERN1
- MAP4K4
- PIM1
- PHKG2
- PFKP
- PEBP1
- PDXK
- PDPK1
- PDGFRB
- PAK6
- PAK4
- PAK2
- PAICS
- OPA1
- NUAK2
- NUAK1
- PIM2
- PIP4K2A
- PIP4K2C
- PRKACB
- PRKCB
- PRKCA
- PRKAR2A
- PRKAG2
- PRKAG1
- PRKACG
- PRKACA
- PKMYT1
- PRKAA1
- PLK3
- PLK1
- PKN3
- PKN2
- PKN1
- NQO2
- NLK
- NEK9
- MAPK9
- MARK4
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
- CP2C9
- CP2D6
- EML4
- HLAB
- IFNB1
- KSYK
- NSD2
- NTM1A
- NTMT1
- TP53
- TSSK1
Drug classes
- Tyrosine Kinase Inhibitors
- Antineoplastic Agents
- Enzyme Inhibitors
- Protein Kinase Inhibitors
- Kinase Inhibitor
- Cytochrome P450 2C9 Inhibitors
- Cytochrome P450 3A Inhibitors
ATC classes
- L01E · PROTEIN KINASE INHIBITORS
Cross-references
Synonyms
- ZYKADIA
- Zykadia
- NVP-LDK378-NX
- zykadia
- LDK378
- CERITINIB[MI]
- 4MK
- CERITINIB (LDK378)
- CPD 15
- LDK-378
- NVP-LDK-378-NX
- LDK 378
- UNII-K418KG2GET
- LDK378(Ceritinib)
- Eritinib (LDK378)
- K418KG2GET
- CHEMBL2403108
- CHEBI:78432
- AK174337
- C28H36ClN5O3S
- ceritinibum
- RefChem:57924
- DTXCID50676118
- L01XE28
- Ceritinib (LDK378)
- MFCD26142648
- Ceritinib(LDK378)
- Ceritinib [USAN:INN]
- Ceritinib[mi]
- Zykadia (TN)
- Ceritinib (Standard)
- Ceritinib; LDK378
- CERITINIB [INN]
- CERITINIB [JAN]
- CERITINIB [MI]
- Ceritinib(LDK378)?
- CERITINIB [USAN]
- CERITINIB [VANDF]
Reported adverse events
- Abdominal pain
- Bradycardia
- Constipation
- Fatigue
- Hepatotoxicity
- Interstitial lung disease
- Nausea
- Pancreatitis
- Pericarditis
- Pneumonitis
- Rash
- Vomiting
Look up CERITINIB in the interactive SynDRA portal →